These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
320 related articles for article (PubMed ID: 15085470)
1. Differentiation of low-molecular-weight heparins: impact on the future of the management of thrombosis. Fareed J; Ma Q; Florian M; Maddineni J; Iqbal O; Hoppensteadt DA; Bick RL Semin Thromb Hemost; 2004 Feb; 30 Suppl 1():89-104. PubMed ID: 15085470 [TBL] [Abstract][Full Text] [Related]
2. Are the available low-molecular-weight heparin preparations the same? Fareed J; Jeske W; Hoppensteadt D; Clarizio R; Walenga JM Semin Thromb Hemost; 1996; 22 Suppl 1():77-91. PubMed ID: 8807734 [TBL] [Abstract][Full Text] [Related]
3. Low molecular weight heparins: are they different? Fareed J; Hoppensteadt D; Jeske W; Clarizio R; Walenga JM Can J Cardiol; 1998 Aug; 14 Suppl E():28E-34E. PubMed ID: 9779031 [TBL] [Abstract][Full Text] [Related]
4. Biochemical and pharmacologic characteristics of Reviparin, a low-molecular-mass heparin. Jeske W; Fareed J; Eschenfelder V; Iqbal O; Hoppensteadt D; Ahsan A Semin Thromb Hemost; 1997; 23(2):119-28. PubMed ID: 9200335 [TBL] [Abstract][Full Text] [Related]
6. Pharmacologic validation of the clinical effects of an optimized low-molecular-weight heparin-reviparin. Fareed J; Jeske W; Eschenfelder V; Iqbal O; Hoppensteadt D; Ahsan A Semin Thromb Hemost; 1995; 21(2):212-27. PubMed ID: 7660144 [TBL] [Abstract][Full Text] [Related]
7. Changing trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged? Fareed J; Iqbal O; Cunanan J; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R Int Angiol; 2008 Jun; 27(3):176-92. PubMed ID: 18506123 [TBL] [Abstract][Full Text] [Related]
8. Product individuality of commercially available low-molecular-weight heparins and their generic versions: therapeutic implications. Maddineni J; Walenga JM; Jeske WP; Hoppensteadt DA; Fareed J; Wahi R; Bick RL Clin Appl Thromb Hemost; 2006 Jul; 12(3):267-76. PubMed ID: 16959680 [TBL] [Abstract][Full Text] [Related]
9. Survival of heparins, oral anticoagulants, and aspirin after the year 2010. Fareed J; Hoppensteadt DA; Fareed D; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R Semin Thromb Hemost; 2008 Feb; 34(1):58-73. PubMed ID: 18393143 [TBL] [Abstract][Full Text] [Related]
11. Differentiating low-molecular-weight heparins based on chemical, biological, and pharmacologic properties: implications for the development of generic versions of low-molecular-weight heparins. Jeske WP; Walenga JM; Hoppensteadt DA; Vandenberg C; Brubaker A; Adiguzel C; Bakhos M; Fareed J Semin Thromb Hemost; 2008 Feb; 34(1):74-85. PubMed ID: 18393144 [TBL] [Abstract][Full Text] [Related]
12. Low molecular weight heparins prevent thrombin-induced thrombo-embolism in mice despite low anti-thrombin activity. Evidence that the inhibition of feed-back activation of thrombin generation confers safety advantages over direct thrombin inhibition. Momi S; Nasimi M; Colucci M; Nenci GG; Gresele P Haematologica; 2001 Mar; 86(3):297-302. PubMed ID: 11255277 [TBL] [Abstract][Full Text] [Related]
14. An update on heparins at the beginning of the new millennium. Fareed J; Hoppensteadt DA; Bick RL Semin Thromb Hemost; 2000; 26 Suppl 1():5-21. PubMed ID: 11011802 [TBL] [Abstract][Full Text] [Related]
15. Past, present and future considerations on low molecular weight heparin differentiation: an epilogue. Fareed J; Haas S; Sasahar A Semin Thromb Hemost; 1999; 25 Suppl 3():145-7. PubMed ID: 10549730 [TBL] [Abstract][Full Text] [Related]
17. Structural and functional characterization of low-molecular-weight heparins: impact on the development of guidelines for generic products. Adiguzel C; Jeske WP; Hoppensteadt D; Walenga JM; Bansal V; Fareed J Clin Appl Thromb Hemost; 2009; 15(2):137-44. PubMed ID: 19357102 [TBL] [Abstract][Full Text] [Related]
18. Comparative antithrombotic potencies of direct thrombin inhibitors and low-molecular-weight heparins in an ex vivo human experimental thrombosis model. Harenberg J; Zokai K; Piazolo L; Fenyvesi T; Jörg I Semin Thromb Hemost; 2002 Aug; 28(4):379-82. PubMed ID: 12244485 [TBL] [Abstract][Full Text] [Related]
19. Management of thrombotic and cardiovascular disorders in the new millenium. Fareed J; Hoppensteadt DA; Bick RL Clin Appl Thromb Hemost; 2003 Apr; 9(2):101-8. PubMed ID: 12812377 [TBL] [Abstract][Full Text] [Related]
20. Preclinical biochemistry and pharmacology of low molecular weight heparins in vivo--studies of venous and arterial thrombosis. Kaiser B; Kirchmaier CM; Breddin HK; Fu K; Fareed J Semin Thromb Hemost; 1999; 25 Suppl 3():35-42. PubMed ID: 10549714 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]